Osteoporosis drugs tied to lower fracture risk and health costs

NEW YORK (Reuters ) – Older women with osteoporosis who consistently take medications for the condition may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a US study suggests.

Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for the first time at some point between 2009 and 2011.

Overall, roughly one third of these women consistently took their medications for at least a year with no gaps of two months or longer. The remaining two-thirds were considered “non-persistent” users because they had even longer lapses in medication use.

Among women who consistently took their drugs, annual fracture rates dropped from 16.2 fractures for every 100 patients in the six months before starting medication to 4.1 fractures for every 100 patients in the first 18 months of using osteoporosis drugs.

Women who were non-persistent users, however, had higher annual fracture rates: 19 fractures for every 100 patients in the six months before starting medication, and 7.3 fractures for every 100 patients over the first 18 months after drugs were prescribed.

“When the medication stops, bone density will decrease again,” Liu said by email.

Many women with osteoporosis are prescribed medicines known as bisphosphonates, which work by slowing down how fast the body removes old bone, allowing time to regrow bone and make fractures less likely. This family of drugs includes Fosamax (alendronate sodium), Actonel (risedronate sodium) and Boniva (ibandronate sodium).

Widespread use of bisphosphonates in the U.S. coincided with a dramatic decline in fractures from the mid-1990s to the mid-2000s. But use of these medicines has declined in recent years following reports of rare, but serious side effects including unusual fractures of the thigh bone, death of bone tissue in the jaw and esophageal cancer.

More than one-third of women prescribed bisphosphonates never fill their first prescription, researchers note in Osteoporosis International.

In the study, about nine in 10 women who didn’t consistently take their medicines stopped refilling their prescriptions.

Total average health costs for patients who didn’t take medicines as prescribed were $19,181 a year, compared with $14,476 for women who consistently took their drugs.

Fracture-related costs were higher without consistent medication use, averaging $641 a year compared with $292 for women who stuck with their medicines.

Without consistent drug use, women also had higher inpatient hospital costs: an average of $6,297 compared with $3,516 for those who did take the medicines.

The study wasn’t a controlled experiment designed to prove whether or how osteoporosis medication use directly reduces the risk of fractures or increases health costs.

Still, the results should reassure patients about the effectiveness of osteoporosis medicines when taken as directed, said Dr. Matthew Drake of the Mayo Clinic in Rochester, Minnesota.

“But they don’t work nearly as effectively when patients do not continue with them,” Drake, who wasn’t involved in the study, said by email.

For elderly patients in particular, fractures can lead to significant reductions in both independence and quality of life, Drake added. Doctors and patients should consider this when weighing whether to start or stop osteoporosis drugs, he said.

“Some use is better than no use,” said Dr. Daniel Solomon, a researcher at Brigham and Women’s Hospital and Harvard Medical School in Boston who wasn’t involved in the study.

“However, using the drugs as prescribed is always recommended,” Solomon said by email.